Neurosoft Bioelectronics SA has signed an agreement with Science Corp. to gain access to its full stack of clinical-grade neural recording tools as it looks to advance its brain-computer interface (BCI) system.
Gilead Sciences Inc. is acquiring partner Arcellx Inc. at a value of up to $7.8 billion, consisting of $115 per share up front and a potential payment of $5 per share through a contingent value right.
Harbour Biomed is spinning out newco Solstice Oncology and is outlicensing its CTLA-4 antibody, porustobart (HBM-4003), to the newco in a cash and equity deal worth more than $1.2 billion.
Swiss pharmaceutical giant Novartis AG is selling off its India-listed business unit, Novartis India Ltd. (NIL), to a private equity-led consortium for about ₹14.46 billion (US$159.3 million) as it seeks to grow with “pure-play innovation.”
CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the deal includes undisclosed milestone payments and sales-based royalties. CSL will retain rights to develop and commercialize clazakizumab for prevention of cardiovascular events in patients with end-stage kidney disease, while Lilly will explore the MAb in all other indications.
Gilead Sciences is stepping deeper into synthetic lethality, licensing a clinic-ready MAT2A (methionine adenosyltransferase 2a) inhibitor from Suzhou, China-based Genhouse Bio Co. Ltd. in a deal worth up to $1.53 billion.
Less than four months after company officials said they would explore options to find ways of maximizing shareholder value, Sensei Biotherapeutics Inc. disclosed the buyout of Faeth Therapeutics Inc. by way of a stock-for-stock deal – news that sent shares (NASDAQ:SNSE) to a closing price Feb. 18 of $26.25, up $17.12, or 187.5%.
Alchemedicine Inc. and Asahi Kasei Pharma Corp. have entered into an exclusive license agreement on lead HiSAP (high solubility and permeability) compounds owned by Alchemedicine.
Biopharma dealmaking continued its momentum into 2026, with January logging $31.16 billion in total value. That figure outpaced January 2025’s $28.63 billion and exceeded the 2025 monthly average of $24.38 billion. In addition, January 2026 ranks as the highest first month in the past eight years.
Continuing to build on the successful launch of Rezdiffra (resmetirom), Madrigal Pharmaceuticals Inc. is adding six preclinical-stage siRNA therapies to its metabolic dysfunction-associated steatohepatitis (MASH) pipeline in a deal with Ribo Life Science Co. Ltd. and its subsidiary, Ribocure Pharmaceuticals AB, that could be worth $4.4 billion if all milestones are achieved.
RSS
